Bioinvent


BioInvent International is a Swedish research, pharmaceutical and life science company with focus on clinical development of antibody drugs for immunotherapy against cancer. The company was founded in 1983 by and is listed on the Stockholm Stock Exchange since 2001. The company's partners include Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe and Servier. Martin Welschof has been CEO since 2018.